"Designing Growth Strategies is in our DNA"

Hepatocellular Carcinoma (HCC) Treatment Market Size, Share and Global Trend by Treatment (Interventional Radiology, Chemotherapy, Radiation Therapy, Surgery, Targeted Therapy, Immunotherapy), By End User (Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgery Centers), and Geography Forecast till 2026

Region : Global | Report ID: FBI100326 | Status : Ongoing

 

KEY MARKET INSIGHTS

Hepatocellular Carcinoma (HCC) is known as malignant hepatoma and is the major malignancy of the liver occurring in patients with chronic liver diseases and cirrhosis. The hepatic tumors proliferate with local expansion, spreading in the intrahepatic region and finally distant metastases. In 2015, in U.S., approximately 39,230 people were affected with intrahepatic bile duct cancer.

The major risks associated with Hepatocellular Carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. In April 2018, Eli Lilly and Company completed Phase 3 research study of Cyramza (ramucirumab) as a single agent in the second-line treatment of people with hepatocellular carcinoma. 

To gain extensive insights into the market, Request for Customization

Technology advancements in the detection and treatment of the hepatocellular carcinoma, personalized medicine, and cost-effective treatment procedures are some of the factors driving the growth of global hepatocellular carcinoma treatment market. Additionally, high exposure to toxins and increasing incidence of hepatocellular carcinoma are some of the factors driving the growth of Global Hepatocellular Carcinoma Treatment Market.

The factor that is expected to inhibit the growth of the market is stringent regulatory processes, the low success rate in clinical trials for drugs, and lack of awareness among the underdeveloped countries.  

Key Players Covered 

Some of the major companies that are present in the global Hepatocellular Carcinoma (HCC) Treatment market are Novartis AG, Bayer AG, Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Johnson & Johnson Services, Inc., CELGENE CORPORATION, Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Company Limited, and others. 

SEGMENTATION 

 

 SEGMENTATION

 DETAILS

By Treatment

·         Interventional Radiology

·         Chemotherapy

·         Radiation Therapy

·         Surgery

·         Targeted Therapy

·         Immunotherapy

·         Others.

By End User

·         Hospitals

·         Clinics

·         Cancer Rehabilitation Centers

·         Ambulatory Surgery Centers

·         Others.

By Geography

·         North America (USA and Canada)

·         Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·         Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·         Latin America (Brazil, Mexico and Rest of Latin America)

·         Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

                               

The interventional radiology segment can be further divided into chemoembolization, intra-arterial chemotherapy, radiofrequency ablation, and others. NanoKnife is a minimally invasive option for some liver cancer patients with an inoperable tumor that is typically less than three centimeters. This segment is expected to have higher demand during the forecast period. 

Key Insights 

  • Prevalence of Hepatocellular Carcinoma, Key Countries/ Region
  • Pipeline Analysis, Key Players  

Regional Analysis 

North America is expected to hold a dominant position in the global hepatocellular carcinoma treatment market over the forecast period, owing to the increasing prevalence of the chronic liver diseases and rising number of clinical trials for the treatment of cancer undertaken by the manufacturers to address the unmet medical needs of the patients. According to a survey conducted by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) represents more than 70.0% of all liver cancers diagnosed in the U.S., with an estimated 40,000 people diagnosed with liver cancer in 2017 and more than 28,000 deaths reported due to hepatocellular carcinoma. Europe and Asia Pacific are expected to register significant CAGR in the forecast period, owing to a rising number of research and development activities undertaken by the manufacturers in the region to develop effective therapies and treatment methods to treat hepatocellular carcinoma. According to the World Health Organization, in Europe and Japan, an estimated 63,000 and 36,000 people were diagnosed with liver cancer in 2017, respectively. 

Key Industry Developments

  • In August 2018, Eisai Co., Ltd., received FDA approval for lenvatinib capsules for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
  • In September 2018, Exelixis, Inc., received approval for Cabometyx for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
  • AstraZeneca currently developing Durvalumab is under phase 3 clinical trial and expected to launch the by 2021.
  • Lion TCR Pte. Ltd., is developing HBV antigen specific TCR redirected T cell under phase 2 trial for the Hepatocellular Carcinoma (HCC) is expected to get over by 2020.

Hepatocellular Carcinoma (HCC) Treatment Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2019
  • 2016-2018

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Healthcare Clients

Natus-Medical
DAEWOONG
DUPONT
baxter
Logo_Merck_KGaA_2015

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X